<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in adults and contributes directly to adverse clinical events, ranging from <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> to <z:hpo ids='HP_0001635'>heart failure</z:hpo> and cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because the incidence of AF and its attendant complications increase with age, there is a strong and growing need to develop safe, effective and widely available therapies </plain></SENT>
<SENT sid="2" pm="."><plain>The following review summarizes the use of oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> in older adults with AF, focusing on practical topics such as drug metabolism, drug-drug interactions, co-morbidities and cost considerations in a complex payer environment </plain></SENT>
</text></document>